Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date
of
Report (date of earliest event reported): September
8, 2008
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
(Exact
name of registrant as specified in charter)
Florida
(State
or
other jurisdiction of incorporation)
|
333-86347
|
|
65-1130026
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
|
(Address
of principal executive offices and zip code)
(0086)
535-7282997
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12(b) under the
Exchange Act (17 CFR 240.14a-12(b))
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 - Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Effective
September 8, 2008, the Board of Directors (the “Board”) of Genesis
Pharmaceuticals Enterprises, Inc. (the “Company”) appointed Mr. John Yang Wang
to serve as a member of the Board of the Company. Mr. Wang, an independent
director, will be a member
of
the Company's
Audit Committee and Compensation Committee. A
press
release was issued on September 10, 2008 to this effect, a copy of which is
attached to this report as Exhibit 99.1.
Mr.
Wang
founded and is the President of Marbella Capital Partners, serves as the CEO
of
Hambrecht Asia Acquisition Corp., and is on the Board of Directors of Hong
Kong
Stock Exchange listed Wuyi International Pharmaceuticals Company Limited. From
2000 to 2004, he was Executive Vice President of SBI E2-Capital (HK) Limited.
From 1997 to 1999, he managed Accenture Consulting’s (formerly known as Andersen
Consulting) Greater China communication, media and high tech strategy practice.
Prior to that, he was the lead telecom analyst covering Greater China and
Southeast Asia for Pyramid Research, an emerging market telecom research firm
based in Cambridge, Massachusetts. Mr. Wang holds a Bachelor of Arts in
International Relations from Tufts University and an M.A.L.D. degree in
international law and business from The Fletcher School of Law and Diplomacy.
He
has over 15 years of experience in investment banking and consulting and speaks
fluent Mandarin and English.
Mr.
Wang
has no family relationship with any of the executive officers or directors
of
the Company. There has been no transaction in the past two years to which the
Company or any of its subsidiaries was or is to be a party, in which Mr. Wang
had, or will have, a direct or indirect material interest.
On
September 9, 2008, the Board accepted the resignation of Mr. Robert
Cain as
a
director of the Company. Mr. Cain’s resignation was not
the
result of any disagreement with the Company on any matter relating to the
Company’s operations, policies or practices. Mr. Cain has entered into a
consulting agreement to provide consulting services to the Company through
December 31, 2008, a copy of which is attached to this report as Exhibit 10.1.
Item
9.01 Financial
Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
| |
|
|
|
10.1
|
|
Consulting
Agreement between the Registrant and Robert Cain, dated September
10,
2008.
|
| |
|
|
|
99.1
|
|
Press
Release dated September 10,
2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
|
| |
|
| |
By:
/s/ Wubo
Cao
|
| |
Name:
Wubo Cao
|
| |
Title:
Chief Executive Officer
|
Dated:
September 12, 2008